Artiva Biotherapeutics, Inc. (ARTV) — SEC Filings
Artiva Biotherapeutics, Inc. (ARTV) — 23 SEC filings. Latest: FWP (May 8, 2026). Includes 6 10-Q, 6 8-K, 2 SC 13G.
View Artiva Biotherapeutics, Inc. on SEC EDGAR
Overview
Artiva Biotherapeutics, Inc. (ARTV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Artiva Biotherapeutics, Inc. announced on December 10, 2025, changes in its board of directors and executive officers. The filing details the departure of certain directors and officers, the election of new directors, and updates to compensatory arrangements for key personnel. These changes are effe
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 20 neutral. The dominant filing sentiment for Artiva Biotherapeutics, Inc. is neutral.
Filing Type Overview
Artiva Biotherapeutics, Inc. (ARTV) has filed 1 FWP, 6 10-Q, 6 8-K, 1 DEF 14A, 1 10-K, 1 SC 13G/A, 1 SC 13D/A, 2 SC 13G, 2 SC 13D, 1 S-1/A, 1 S-1 with the SEC between Jun 2024 to May 2026.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of ARTV's 16 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$21.5M |
| EPS | N/A |
| Debt-to-Equity | 0.15 |
| Cash Position | $123.0M |
| Operating Margin | N/A |
| Total Assets | $148.9M |
| Total Debt | $19.6M |
Key Executives
- San Diego, California
- Peter Kolchinsky
- Rajeev Shah
- Yong-Jun Huh
- Fred Aslan, M.D.
- Jennifer Bush
- Carlos Ramirez
- Charles S. Kim
Industry Context
Artiva Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on achieving clinical milestones and securing substantial funding for ongoing research and trials.
Top Tags
biotech (4) · corporate-governance (3) · 10-Q (3) · biotechnology (3) · filing (3) · leadership-change (2) · Biotechnology (2) · Clinical Trials (2) · Net Loss (2) · R&D Expenses (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $21.5M | Increased from $17.5M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $63.1M | Widened from $49.3M in YTD Q3 2024 |
| Research and Development Expenses (YTD Q3 2025) | $52.5M | Increased from $37.0M in YTD Q3 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $25.5M | Decreased from $40.2M at Dec 31, 2024 |
| Short-term Investments (Sept 30, 2025) | $97.5M | Decreased from $145.2M at Dec 31, 2024 |
| Accumulated Deficit (Sept 30, 2025) | $309.8M | Increased from $246.7M at Dec 31, 2024 |
| Common Shares Outstanding (Oct 31, 2025) | 24,544,904 | Increased from 24,291,607 at Dec 31, 2024 |
| Net Loss | $24.7 million | for the three months ended June 30, 2025, increased from $18.9 million in 2024 |
| Collaboration Revenue | $1.1 million | for the three months ended June 30, 2025, decreased from $1.5 million in 2024 |
| Research and Development Expenses | $20.1 million | for the three months ended June 30, 2025, increased from $15.6 million in 2024 |
| Cash and Cash Equivalents | $105.3 million | as of June 30, 2025, decreased from $130.1 million at December 31, 2024 |
| SEC File Number | 001-42179 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 83-3614316 | Company's tax identification number. |
| Fiscal Year End | 2024 | The proxy statement covers the company's performance and governance for this period. |
| Reporting Period End Date | 2024-09-30 | The 10-Q covers financial information up to this date. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Artiva Biotherapeutics, Inc. (ARTV)?
Artiva Biotherapeutics, Inc. has 23 recent SEC filings from Jun 2024 to May 2026, including 6 10-Q, 6 8-K, 2 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ARTV filings?
Across 23 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 20 neutral. The dominant sentiment is neutral.
Where can I find Artiva Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Artiva Biotherapeutics, Inc. (ARTV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Artiva Biotherapeutics, Inc.?
Key financial highlights from Artiva Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ARTV?
The investment thesis for ARTV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Artiva Biotherapeutics, Inc.?
Key executives identified across Artiva Biotherapeutics, Inc.'s filings include San Diego, California, Peter Kolchinsky, Rajeev Shah, Yong-Jun Huh, Fred Aslan, M.D. and 3 others.
What are the main risk factors for Artiva Biotherapeutics, Inc. stock?
Of ARTV's 16 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Artiva Biotherapeutics, Inc.?
Forward guidance and predictions for Artiva Biotherapeutics, Inc. are extracted from SEC filings as they are enriched.